Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089 · see citing works

Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity

Guerre-Millo, M., Gervois, P., Raspé, E., Madsen, L., Poulain, P., Derudas, B., Herbert, J.-M., Winegar, D. A., Willson, T. M., Fruchart, J.-C., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.22.16638 · Cited by 605 · see citing works

Adiponectin Increases Fatty Acid Oxidation in Skeletal Muscle Cells by Sequential Activation of AMP-Activated Protein Kinase, p38 Mitogen-Activated Protein Kinase, and Peroxisome Proliferator–Activated Receptor α

Yoon, M. J., Lee, G. Y., Chung, J.-J., Ahn, Y. H., Hong, S. H., & Kim, J. B. (2006) · Diabetes · doi:10.2337/db05-1322 · Cited by 546 · see citing works

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: Hepatology

Staels, B., Rubenstrunk, A., Noel, B., Rigou, G., Delataille, P., Millatt, L. J., Baron, M., Lucas, A., Tailleux, A., Hum, D. W., et al. (2013) · Hepatology · doi:10.1002/hep.26461 · Cited by 414 · see citing works

Steatohepatitis, Spontaneous Peroxisome Proliferation and Liver Tumors in Mice Lacking Peroxisomal Fatty Acyl-CoA Oxidase

Fan, C.-Y., Pan, J., Usuda, N., Yeldandi, A. V., Rao, M. S., & Reddy, J. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.25.15639 · Cited by 343 · see citing works

Global Suppression of IL-6-induced Acute Phase Response Gene Expression after Chronic in Vivo Treatment with the Peroxisome Proliferator-activated Receptor-α Activator Fenofibrate

Gervois, P., Kleemann, R., Pilon, A., Percevault, F., Koenig, W., Staels, B., & Kooistra, T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400346200 · Cited by 212 · see citing works

Fat Aussie—A New Alström Syndrome Mouse Showing a Critical Role for ALMS1 in Obesity, Diabetes, and Spermatogenesis

Arsov, T., Silva, D. G., O’Bryan, M. K., Sainsbury, A., Lee, N. J., Kennedy, C., Manji, S. S. M., Nelms, K., Liu, C., Vinuesa, C. G., et al. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0494 · Cited by 166 · see citing works

Type 2 immunity in tissue repair and fibrosis

Gieseck, R. L., Wilson, M. S., & Wynn, T. A. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.90 · Cited by 1,055 · see citing works

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035 · see citing works

PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD

Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778 · see citing works

Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases

Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745 · see citing works

Targeting fibrosis: mechanisms and clinical trials

Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547 · see citing works

New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond

Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537 · see citing works

NAFLD as a driver of chronic kidney disease

Byrne, C. D., & Targher, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.01.013 · Cited by 449 · see citing works

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors

Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316 · see citing works

Differential Effects of Selective- and Pan-PPAR Agonists on Experimental Steatohepatitis and Hepatic Macrophages(☆)

Lefere, S., Puengel, T., Hundertmark, J., Penners, C., Frank, A. K., Guillot, A., de Muynck, K., Heymann, F., Adarbes, V., Defrêne, E., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.025 · Cited by 310 · see citing works

Regulation of Ketone Body Metabolism and the Role of PPARα

Grabacka, M., Pierzchalska, M., Dean, M., & Reiss, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122093 · Cited by 305 · see citing works

Primary biliary cholangitis: pathogenesis and therapeutic opportunities

Gulamhusein, A. F., & Hirschfield, G. M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0226-7 · Cited by 308 · see citing works

PPARs as Nuclear Receptors for Nutrient and Energy Metabolism

Hong, F., Pan, S., Guo, Y., Xu, P., & Zhai, Y. (2019) · Molecules · doi:10.3390/molecules24142545 · Cited by 233 · see citing works

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

Nakajima, A., Eguchi, Y., Yoneda, M., Imajo, K., Tamaki, N., Suganami, H., Nojima, T., Tanigawa, R., Iizuka, M., Iida, Y., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16596 · Cited by 213 · see citing works

Novel therapeutic targets for cholestatic and fatty liver disease

Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204 · see citing works

Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling

Manca, C., Boubertakh, B., Leblanc, N., Deschênes, T., Lacroix, S., Martin, C., Houde, A., Veilleux, A., Flamand, N., Muccioli, G. G., et al. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000424 · Cited by 152 · see citing works

Role of natural phenolics in hepatoprotection: A mechanistic review and analysis of regulatory network of associated genes

Saha, P., Talukdar, A. D., Nath, R., Sarker, S. D., Nahar, L., Sahu, J., & Choudhury, M. D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00509 · Cited by 148 · see citing works

The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis

Hennuyer, N., Duplan, I., Paquet, C., Vanhoutte, J., Woitrain, E., Touche, V., Colin, S., Vallez, E., Lestavel, S., Lefebvre, P., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.003 · Cited by 132 · see citing works

Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPARα-regulated dermatopontin

Lefebvre, P., Lalloyer, F., Baugé, E., Pawlak, M., Gheeraert, C., Dehondt, H., Vanhoutte, J., Woitrain, E., Hennuyer, N., Mazuy, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92264 · Cited by 117 · see citing works

Multi-omics analysis of multiple missions to space reveal a theme of lipid dysregulation in mouse liver

Beheshti, A., Chakravarty, K., Fogle, H., Fazelinia, H., Silveira, W. A. D., Boyko, V., Polo, S.-H. L., Saravia-Butler, A. M., Hardiman, G., Taylor, D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55869-2 · Cited by 90 · see citing works

Kefir and Intestinal Microbiota Modulation: Implications in Human Health

Peluzio, M. D. C. G., Dias, M. D. M. E., Martinez, J. A., & Milagro, F. I. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.638740 · Cited by 92 · see citing works

Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells

Chen, L., Li, L., Chen, J., Li, L., Zheng, Z., Ren, J., & Qiu, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.6466 · Cited by 83 · see citing works

Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD

Pierantonelli, I., Rychlicki, C., Agostinelli, L., Giordano, D. M., Gaggini, M., Fraumene, C., Saponaro, C., Manghina, V., Sartini, L., Mingarelli, E., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-11744-6 · Cited by 82 · see citing works

Immunopathogenic mechanisms and immunoregulatory therapies in MASLD

He, Y., Chen, Y., Qian, S., van Der Merwe, S., Dhar, D., Brenner, D. A., & Tacke, F. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01307-5 · Cited by 81 · see citing works

Single-nucleus RNA-seq2 reveals functional crosstalk between liver zonation and ploidy

Richter, M. L., Deligiannis, I. K., Yin, K., Danese, A., Lleshi, E., Coupland, P., Vallejos, C. A., Matchett, K. P., Henderson, N. C., Colome-Tatche, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24543-5 · Cited by 75 · see citing works

Nuclear receptors in liver fibrosis

Königshofer, P., Brusilovskaya, K., Petrenko, O., Hofer, B. S., Schwabl, P., Trauner, M., & Reiberger, T. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166235 · Cited by 45 · see citing works

Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice

Du, M., Wang, X., Yuan, L., Liu, B., Mao, X., Huang, D., Yang, L., Huang, K., Zhang, F., Wang, Y., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.030 · Cited by 41 · see citing works

Impact of PPAR-Alpha Polymorphisms—The Case of Metabolic Disorders and Atherosclerosis

Ruscica, M., Busnelli, M., Runfola, E., Corsini, A., & Sirtori, C. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184378 · Cited by 33 · see citing works

<i>Salvia hispanica</i> L. (chia) seed ameliorates liver injury and oxidative stress by modulating NrF2 and NFκB expression in sucrose-rich diet-fed rats

Vega Joubert, M. B., Ingaramo, P., Oliva, M. E., & D'Alessandro, M. E. (2022) · Food &amp; Function · doi:10.1039/d2fo00642a · Cited by 25 · see citing works

Nanodrug rescues liver fibrosis via synergistic therapy with H2O2 depletion and Saikosaponin b1 sustained release

Peng, M., Shao, M., Dong, H., Han, X., Hao, M., Yang, Q., Lyu, Q., Tang, D., Shen, Z., Wang, K., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04473-2 · Cited by 22 · see citing works

Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis

Caines, A., Trudeau, S., & Gordon, S. C. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2390120 · Cited by 7 · see citing works

Engineered Perfusable Hepatic Fibrosis Model via Embedded Sacrificial Bioprinting Recapitulates Stiffness‐Driven Fibrogenesis

Lv, W., Naren, T., Aazmi, A., Yu, H., Wang, Y., Lee, J. Y., Yu, M., Jia, J., Jiang, X., Yang, H., et al. (2026) · Advanced Materials · doi:10.1002/adma.202513401 · Cited by 5 · see citing works

The natural product-derived JM-9 alleviates high-fat diet-induced fatty liver in mice by targeting MD2

Jin, L., Cui, Y., Zhang, Q., Xiong, Y., Zheng, X., Ye, J., Zhang, A., Xiao, Z., Zhuang, Z., Liang, G., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114053 · Cited by 1 · see citing works

Pharmacological effects and molecular targets of L-theanine in cardiovascular diseases and comorbidities

García-Niño, W. R., Zúñiga-Muñoz, A. M., & Maldonado-Macías, X. P. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178715 · Cited by 1 · see citing works